Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 4, 2013, Pages 338-344

  Ptaszynski, Pawel ^a   Kaczmarek, Krzysztof ^a   Ruta, Jan ^a   Klingenheben, Thomas ^b   Cygankiewicz, Iwona ^a   Wranicz, Jerzy K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Cardiology Practice Bonn   (Germany)

Author keywords

heart rate; inappropriate sinus tachycardia; ivabradine; metoprolol

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; SARTAN DERIVATIVE; VERAPAMIL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; EUROPEAN HEART RHYTHM ASSOCIATION SCORE; FEMALE; HEART RATE; HOLTER MONITORING; HUMAN; INAPPROPRIATE SINUS TACHYCARDIA; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SINUS TACHYCARDIA;

HEART RATE; INAPPROPRIATE SINUS TACHYCARDIA; IVABRADINE; METOPROLOL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BENZAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE TEST; FEMALE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; TACHYCARDIA, SINUS; TREATMENT OUTCOME;

EID: 84879225171     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248413478172     Document Type: Article

References (22)

1. Femenía F, Baranchuk A, Morillo CA. Inappropriate sinus tachycardia: current therapeutic options. Cardiol Rev. 2012 ; 20 (1). 8-14
2. Still AM, Raatikainen P, Ylitalo A, et al. Prevalence, characteristics and natural course of inappropriate sinus tachycardia. Europace. 2005 ; 7 (2). 104-112
3. Morillo CA, Klein GJ, Thakur RK, Li H, Zardini M, Yee R. Mechanism of 'inappropriate' sinus tachycardia. Role of sympathovagal balance. Circulation. 1994 ; 90 (2). 873-877
4. Leon H, Guzman J, Kuusela T, Dillenburg R, Kamath M, Morillo CA. Impaired baroreflex gain in patients with inappropriate sinus tachycardia. J Cardiovasc Electrophysiol. 2005 ; 16 (1). 64-68
5. Shen WK. Modification and ablation for inappropriate sinus tachycardia: current status. Card Electrophysiol Rev. 2002 ; 6 (4). 349-355
6. Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. J Am Coll Cardiol. 2000 ; 35 (2). 451-457
7. Marrouche NF, Beheiry S, Tomassoni G, et al. Three-dimensional nonfluoroscopic mapping and ablation of inappropriate sinus tachycardia. Procedural strategies and long-term outcome. J Am Coll Cardiol. 2002 ; 39 (6). 1046-1054
8. Mason PK, DiMarco JP. New pharmacological agents for arrhythmias. Circ Arrhythm Electrophysiol. 2009 ; 2 (5). 588-597
9. Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. Wien Klin Wochensch. 2009 ; 121 (21-22). 716-718
10. Calò L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010 ; 7 (9). 1318-1323
11. Kaplinsky E, Comes FP, Urondo LS, Ayma FP. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessment. Cardiol J. 2010 ; 17 (2). 166-171
12. Zellerhoff S, Hinterseer M, Felix Krull B, et al. Ivabradine in patients with inappropriate sinus tachycardia. Naunyn-Schmied Arch Pharmacol. 2010 ; 382 (5-6). 483-486
13. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013 ; 15 (1). 116-121
14. Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012 ; 60 (15). 1323-1329
15. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet. 2008 ; 372 (9641). 807-816
16. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010 ; 376 (9744). 875-885
17. Joannides R, Moore N, Iacob M, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006 ; 61 (2). 127-137
18. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005 ; 26 (23). 2529-2536
19. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009 ; 30 (5). 540-548
20. Werdan K, Ebelt H, Nuding S, Höpfner F, Hack G, Müller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012 ; 101 (5). 365-373
21. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011 ; 25 (6). 531-537
22. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J. 2007 ; 28 (22). 2803-2817